RxSight, Inc. raised earnings guidance for the full year of 2023. For the year, company expects Revenue of $85.0 million to $87.0 million, representing implied growth of 73% to 78% compared to 2022, up from prior guidance of $81.0 million to $86.0 million and Gross margin in the range of 60% to 61%, representing an implied increase of 36% to 39% compared to 2022, up from prior guidance of 58% to 60%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
58.47 USD | -1.76% | -3.50% | +45.01% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+45.01% | 2.32B | |
-7.16% | 177B | |
-4.86% | 65.54B | |
-4.28% | 47.09B | |
+10.32% | 43.43B | |
+8.14% | 41.77B | |
+15.76% | 29.55B | |
+15.53% | 24.83B | |
-5.88% | 23.97B | |
-5.38% | 23.54B |
- Stock Market
- Equities
- RXST Stock
- News RxSight, Inc.
- Rxsight, Inc. Raises Earnings Guidance for the Full Year of 2023